immunotherapy, adoptive

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei Nukaya, Hideto Chono, Junichi Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003811; DOI: 10.1136/jitc-2021-003811
PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S Lopez, Rachel H Ng, Neena Leggett, Vanessa D Jonsson, Jelani C Zarif, Peter P Lee, Xiuli Wang, Catalina Martinez, Tanya B Dorff, Stephen J Forman, Saul J Priceman

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004400; DOI: 10.1136/jitc-2021-004400
Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress
Stefanie Renken, Takahiro Nakajima, Isabelle Magalhaes, Jonas Mattsson, Andreas Lundqvist, Elias S J Arnér, Rolf Kiessling, Stina Linnea Wickström

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004458; DOI: 10.1136/jitc-2021-004458
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
Yi-Chiu Kuo, Cheng-Fu Kuo, Kurt Jenkins, Alfur Fu-Hsin Hung, Wen-Chung Chang, Miso Park, Brenda Aguilar, Renate Starr, Jonathan Hibbard, Christine Brown, John C Williams

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e003752; DOI: 10.1136/jitc-2021-003752
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
Rosa A van Amerongen, Renate S Hagedoorn, Dennis F G Remst, Danique C Assendelft, Dirk M van der Steen, Anne K Wouters, Marian van de Meent, Michel G D Kester, Arnoud H de Ru, Marieke Griffioen, Peter A van Veelen, J H Frederik Falkenburg, Mirjam H M Heemskerk

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004409; DOI: 10.1136/jitc-2021-004409
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Sainiteesh Maddineni, John L Silberstein, John B Sunwoo

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004693; DOI: 10.1136/jitc-2022-004693
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
Sonia Guedan, Maik Luu, Delphine Ammar, Paula Barbao, Chiara Bonini, Philippe Bousso, Christian J Buchholz, Monica Casucci, Biagio De Angelis, Emmanuel Donnadieu, David Espie, Beatrice Greco, Richard Groen, Johannes B Huppa, Chahrazade Kantari-Mimoun, Bruno Laugel, Mary Mantock, Janet L Markman, Emma Morris, Concetta Quintarelli, Michael Rade, Kristin Reiche, Alba Rodriguez-Garcia, Juan Roberto Rodriguez-Madoz, Eliana Ruggiero, Maria Themeli, Michael Hudecek, Ibtissam Marchiq

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e003487; DOI: 10.1136/jitc-2021-003487
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Constance M Yuan, Hao-Wei Wang, Maryalice Stetler-Stevenson, Crystal Mackall, Terry J Fry, Sandhya Panch, Steven Highfill, David Stroncek, Lauren Little, Daniel W Lee, Haneen Shalabi, Bonnie Yates, Nirali Shah

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004483; DOI: 10.1136/jitc-2021-004483
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation
Audrey Moatti, Anais Debesset, Caroline Pilon, Asma Beldi-Ferchiou, Mathieu Leclerc, Rabah Redjoul, Frederic Charlotte, Nhu Hanh To, Adeline Bak, Yazid Belkacemi, Benoît Laurent Salomon, Fadi Issa, David Michonneau, Sebastien Maury, José Laurent Cohen, Allan Thiolat

Journal for ImmunoTherapy of Cancer Apr 2022, 10 (4) e003508; DOI: 10.1136/jitc-2021-003508
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
Kristin G Anderson, Shannon K Oda, Breanna M Bates, Madison G Burnett, Magdalia Rodgers Suarez, Susan L Ruskin, Philip D Greenberg

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003959; DOI: 10.1136/jitc-2021-003959

Main menu

immunotherapy, adoptive

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

immunotherapy, adoptive

Pages